Affiliation:
1. North-Western State Medical University named after I. I. Mechnikov
Abstract
In recent decades, women are increasingly contact the doctors with problems of hypoactive sexual desire disorders (HSDD). Female libido is considered as one of the important indicators of quality of life, sexual health. Therapy of HSDD is difficult due to insufficient knowledge by doctors of both complex, multiple pathogenetic mechanisms of libido reduction and modern therapeutic approaches. In this article, the female sexual desire is considered from the point of view of the biopsychosocial approach, recognized as the leading one when working with sexual dysfunctions. According to biopsychosocial approach, HSDD is a consequence of combined disorders at various levels of human functioning (somatic, personal-psychological and individual-social). Modern conceptual models of sexual desire are presented, on the basis of which therapeutic approaches to HSDD are developed. The most effective from the evidence point of view directions of therapy of HSDD in women – elimination of biomedical factors that violate libido, psychotherapeutic measures (sexual awareness, cognitive behavioral therapy, sexual therapy) are discussed. Evidence-based studies confirming the high effectiveness of an integrative approach to the therapy of HSDD, combining sexual awareness, CBT, sexual therapy and pharmacotherapy, are presented. A new Russian drug – a peptide created specifically for the treatment of HSDD in women is presented. The drug has passed all stages of clinical trials and can be used both in the treatment of idiopathic HSDD and as part of combine therapy (in combination with psychotherapy and sextherapy).